EP4732002A2 - Signatures moléculaires de risque de carcinome hépatocellulaire à long terme dans une stéatose hépatique non alcoolique - Google Patents

Signatures moléculaires de risque de carcinome hépatocellulaire à long terme dans une stéatose hépatique non alcoolique

Info

Publication number
EP4732002A2
EP4732002A2 EP24826776.7A EP24826776A EP4732002A2 EP 4732002 A2 EP4732002 A2 EP 4732002A2 EP 24826776 A EP24826776 A EP 24826776A EP 4732002 A2 EP4732002 A2 EP 4732002A2
Authority
EP
European Patent Office
Prior art keywords
nafld
score
subject
plsec
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24826776.7A
Other languages
German (de)
English (en)
Inventor
Yujin Hoshida
Naoto Fujiwara
Amit Singal
Thomas Baumert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Hopitaux Universitaires de Strasbourg HUS
University of Texas System
University of Texas at Austin
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Hopitaux Universitaires de Strasbourg HUS
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Strasbourg, Hopitaux Universitaires de Strasbourg HUS, University of Texas System, University of Texas at Austin filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of EP4732002A2 publication Critical patent/EP4732002A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente divulgation concerne des méthodes et des compositions pour prédire un risque élevé et faible pour un carcinome hépatocellulaire chez des patients atteints d'une stéatose hépatique non alcoolique (NAFLD). L'invention concerne des méthodes d'identification du NAFLD en tant que NAFLD indolent, progressif ou avancé. Sur la base des résultats obtenus à partir des méthodes et des compositions présentement divulguées, des patients atteints de stéatose hépatique non alcoolique peuvent être classés en un groupe de risque pronostique, ce qui permet un diagnostic précoce et une prévention d'un carcinome hépatocellulaire et d'autres complications mortelles. Les méthodes et les compositions présentement divulguées améliorent sensiblement le mauvais pronostic de sujets présentant ou risquant un carcinome hépatocellulaire.
EP24826776.7A 2023-06-21 2024-06-21 Signatures moléculaires de risque de carcinome hépatocellulaire à long terme dans une stéatose hépatique non alcoolique Pending EP4732002A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363509362P 2023-06-21 2023-06-21
PCT/US2024/035118 WO2024263988A2 (fr) 2023-06-21 2024-06-21 Signatures moléculaires de risque de carcinome hépatocellulaire à long terme dans une stéatose hépatique non alcoolique

Publications (1)

Publication Number Publication Date
EP4732002A2 true EP4732002A2 (fr) 2026-04-29

Family

ID=93936326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24826776.7A Pending EP4732002A2 (fr) 2023-06-21 2024-06-21 Signatures moléculaires de risque de carcinome hépatocellulaire à long terme dans une stéatose hépatique non alcoolique

Country Status (2)

Country Link
EP (1) EP4732002A2 (fr)
WO (1) WO2024263988A2 (fr)

Also Published As

Publication number Publication date
WO2024263988A2 (fr) 2024-12-26
WO2024263988A3 (fr) 2025-05-15

Similar Documents

Publication Publication Date Title
Solé et al. Discovery and validation of new potential biomarkers for early detection of colon cancer
Wozniak et al. Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States
Ameling et al. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy
Warnecke-Eberz et al. Diagnostic marker signature for esophageal cancer from transcriptome analysis
JP2015536667A (ja) 癌のための分子診断検査
JP5690588B2 (ja) 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
JP2016500512A (ja) 肝臓サンプルの分類ならびに限局性結節性異形成、肝細胞腺腫および肝細胞癌の診断のための新規方法
CN104508143A (zh) 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物
WO2017077499A1 (fr) Biomarqueurs du carcinome squameux de la tête et du cou, marqueurs de pronostic de récurrence du carcinome squameux de la tête et du cou, et procédés associés
US20210363593A1 (en) CXCL13 Marker For Predicting Immunotherapeutic Responsiveness In Patient With Lung Cancer And Use Thereof
WO2022053065A1 (fr) Biomarqueur utilisé pour prédire ou évaluer des patients atteints d'un cancer du poumon, procédé de détection et application
US12523658B2 (en) Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
Zhang et al. Identification and characterization of alcohol-related hepatocellular carcinoma prognostic subtypes based on an integrative N6-methyladenosine methylation model
CN113444798A (zh) 肾癌生存风险生物标志物群及诊断产品和应用
Lasham et al. A predictor of early disease recurrence in patients with breast cancer using a cell-free RNA and protein liquid biopsy
WO2013158722A1 (fr) Diagnostic de l'état des ganglions lymphatiques dans le cancer du rectum
JP6951463B2 (ja) 肝細胞癌（ｈｃｃ）または胆管癌（ｃｃａ）を有する被験者の生存転帰を予測する方法
Zhang et al. Proteome microarray identifies autoantibody biomarkers for diagnosis of hepatitis B-related hepatocellular carcinoma
EP4616202A1 (fr) Signatures moléculaires pour prédire la progression d'une fibrose hépatique à long terme
WO2024263988A2 (fr) Signatures moléculaires de risque de carcinome hépatocellulaire à long terme dans une stéatose hépatique non alcoolique
Yu et al. Interferon-inducible protein 16 may be a biomarker and prognostic factor in renal cell carcinoma by bioinformatics analysis
TWI507412B (zh) Gastric cancer biological markers and their use, as well as gastric cancer-related detection methods
EP3931570A1 (fr) Carcinome ovarien séreux de haut grade (hgsoc)
US20150011411A1 (en) Biomarkers of cancer
CN116479123A (zh) m7G相关lncRNA作为生物标志物在肝癌预后或治疗反应预测中的应用及产品和系统

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260107

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR